Full history for every metric is available with a Kvantra account
Metacrine, Inc. (MTCR)
Key financial summary
Financials in USD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | - | 1 | 0 | 0 | 0 | 0 |
| Operating profit | $m | -61 | -37 | |||||
| Net profit | $m | - | - | -26 | -29 | -36 | -61 | -39 |
| EPS reported | $ | -1.45 | -0.93 | |||||
| Operating cashflow per share | $ | -1.12 | -1.12 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -1.12 | -1.12 | |||||
| Free cash flow | $m | -47 | -36 | |||||
| Net debt | $m | -62 | -39 | |||||
| Book value equity | $m | 57 | 37 | |||||
| Book value per share | $ | 1.36 | 0.87 | |||||
| Number of shares | m | 42.11 | 42.57 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.49 | 0.67 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -0.60 | -0.68 | |||||
| EV/EBITDA LTM | x | 0.56 | 0.40 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -215.70% | -250.12% | |||||
| FCF Yield | % | -166.15% | -146.36% | |||||
| Quality | ||||||||
| ROE | % | -106.76% | -83.52% | |||||
| ROIC | % | -82.30% | -82.30% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -3.34 | -2.63 | |||||
| Net Debt/EBITDA | x | 1.04 | 1.04 | |||||
| EBIT/Net interest | x | -50.81 | -50.81 | |||||
| Net debt/market cap | % | -219.44% | -157.43% | |||||
| Net debt/Equity | x | -1.09 | -1.05 | |||||
| Gross debt/equity | x | 0.25 | 0.37 | |||||
Company overview
Metacrine, Inc., established in 2014 and operating from its headquarters in San Diego, California, is a clinical-stage biopharmaceutical company. The firm's core mission involves identifying and advancing novel therapies specifically designed for patients suffering from gastrointestinal disorders. Among its developmental pipeline, Metacrine is progressing MET642, a therapeutic candidate which has successfully completed its Phase I clinical investigation aimed at treating ulcerative colitis.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Metacrine, Inc. (MTCR)
Metacrine, Inc., established in 2014 and operating from its headquarters in San Diego, California, is a clinical-stage biopharmaceutical company. The firm's core mission involves identifying and advancing novel therapies specifically designed for patients suffering from gastrointestinal disorders. Among its developmental pipeline, Metacrine is progressing MET642, a therapeutic candidate which has successfully completed its Phase I clinical investigation aimed at treating ulcerative colitis.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free